DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

Information source: University of Rochester
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Insomnia; Fatigue; Breast Cancer

Intervention: armodafinil (Drug); Placebo Comparator (Drug); CBT-I (Behavioral)

Phase: Phase 2

Status: Recruiting

Sponsored by: University of Rochester

Official(s) and/or principal investigator(s):
Joseph A Roscoe, PhD, Principal Investigator, Affiliation: University of Rochester

Overall contact:
Jenine Hoefler, Phone: 585-276-3559, Email: Jenine_Hoefler@urmc.rochester.edu

Summary

This is a four-arm, randomized, controlled, clinical trial examining the efficacy of of cognitive behavioral therapy (CBT)-I and armodafinil in reducing insomnia in 226 female breast cancer patients who report sleep disturbances following completion of chemotherapy.

Clinical Details

Official title: Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome: To determine if one or more of the intervention strategies (i.e., CBT-I, armodafinil, or both), when compared to a placebo only group, reduce insomnia in breast cancer patients following the conclusion of chemotherapy.

Secondary outcome: All three intervention strategies, as compared to the placebo only group, will reduce fatigue in patients, where the largest effects will occur with the two conditions that utilize armodafinil.

Detailed description: Treatment Protocol: CBT-I and armodafinil are being studied in a four-arm, randomized, controlled, clinical trial of 226 cancer survivors with chronic insomnia who are at least one month post treatment. The seven-week intervention is designed to determine the efficacy and acceptability of these treatment strategies in reducing insomnia and fatigue and in improving QOL in cancer survivors. Assessments will be made by diary and by questionnaires before, during, two weeks following, and three months following the study intervention. All ancillary treatments, as appropriate for control of symptoms caused by the cancer or its treatment may be administered as clinically indicated.

Withdrawal of Sleep Medications: All participants, prior to beginning the baseline data collection phase of the study, must have withdrawn from all sleep medications, including: prescription, over-the-counter, CAM and herbal remedies for at least one week prior to beginning the study.

CBT-I (Arms 3 & 4): CBT-I will be provided on an individual basis to all patients in study Arms 3 & 4 by a licensed clinical psychologist trained in CBT-I by Dr. Perlis. Subjects in these two study arms will receive 7 weeks of CBT-I, using a structured research grade protocol developed at the UR-SNRL. This manualized intervention, which exists as a published text: Perlis et al., 2005, includes four essential components: Sleep Restriction Therapy, Stimulus Control Instruction, Sleep Hygiene Guidelines, and a session of cognitive therapy.

Data Collection: Patients will complete assessments i. e., ESS/KSS, ISI, BFI, FACIT, PHQ-9, GODIN, and Medical Symptoms every Friday during weeks 3-11 of the study and again during weeks 23 and 24. In addition, the IDS will be completed on Fridays during weeks 9, 11, and 24 and patients will complete the PSQI, medication log, and feedback questionnaire on Fridays during weeks 11, and 24. A follow-up call by study personnel will be made to each participant not currently receiving CBT-I on each of these Fridays to promote compliance, prompt completion, assess potential side effects of study medication, and answer patient questions. Study participants will also be required to maintain a daily sleep diary for the initial 11 weeks of the study (i. e., baseline, intervention, and post period) and for two weeks at follow-up (Weeks 23 and 24).

Eligibility

Minimum age: 21 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Have a diagnosis of cancer.

2. Be able to understand written and spoken English

3. Be able to swallow medication

4. Have preferred sleep phase between 7: 30 pm and 11: 00 am

5. Be willing to discontinue any medications/OTCs/Herbals for sleep for the 11-week study period

6. Be presumed to be in a state of cancer remission; use of tamoxifen, an aromatase inhibitor, and/or Herceptin is permitted

7. Self-report problems with insomnia for at least three months and that the insomnia began or got worse with the onset of cancer or treatment

8. Have completed chemotherapy and or radiation not less than one month ago. Note: Both types of treatment must be completed at least one month ago if patient receives chemotherapy and radiation therapy and there is no outer limit to how long ago treatments were completed.)

9. Report insomnia on the SDS-CL at a frequency of at least 3 days a week

Exclusion Criteria:

1. Have ever taken modafinil or had CBT-I therapy. CBT-I therapy for the sake of this protocol will be defined as any cognitive behavioral-based treatment for insomnia that includes a sleep restriction component.

2. Have an unstable medical or psychiatric illness (Axis I-current or within the last 5 years)

3. Have a history of seizures or severe headaches, or uncontrolled cardiac disease or hypertension

4. Be presently taking an anticoagulant or a corticosteroid

5. Have taken amphetamines (e. g., methylphenidate, pemoline [Cylert®] or similar psycho stimulants) within the past 30 days

6. Be currently pregnant or nursing

7. Have a history of substance abuse, or meet criteria for current alcohol abuse or dependence as assessed by a CAGE test score >=2 or an Alcohol Use Disorders Identification Test (AUDIT) score >=13

8. Have surgery planned within the study period

9. Have have ever been diagnosed with sleep apnea or have sleep apnea as indicated by endorsing either question 11 (I wake up choking or gasping for air) or question 12 (My bed partner has noticed that I seem to stop breathing) on the Sleep Disorders Symptom Check at the "Often" or "Frequently" level.

Locations and Contacts

Jenine Hoefler, Phone: 585-276-3559, Email: Jenine_Hoefler@urmc.rochester.edu

University of Rochester James P. Wilmot Cancer Center, Rochester, New York 14642, United States; Recruiting

Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States; Recruiting
Holly Barilla, Phone: 215-746-4384, Email: hbarilla@exchange.upenn.edu
Michael L Perlis, Ph.D., Principal Investigator

Additional Information

Starting date: February 2008
Last updated: November 1, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014